ArticleJournal of medicinal chemistry2011

Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.

Anna E Maciag et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.